MX2017001642A - ANTICUERPO IGß ANTIHUMANO NOVEDOSO. - Google Patents
ANTICUERPO IGß ANTIHUMANO NOVEDOSO.Info
- Publication number
- MX2017001642A MX2017001642A MX2017001642A MX2017001642A MX2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- seq
- acid sequence
- human
- numbers
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 7
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 3
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Problema. Se proporciona un anticuerpo Igß antihumano en el cual BCR y Fc?RIlb se entrecruzan y tiene una función inmunosupresora mejorada en comparación con los anticuerpos convencionales. Solución. Un anticuerpo lgß antihumano que incluye: una región variable de cadena pesada que comprende CDR1 que consiste en la secuencia de aminoácidos de los números de aminoácidos 31 a 35 de la SEC ID NO: 2, CDR2 que consiste en la secuencia de aminoácidos de los números de aminoácidos 50 a 65 de la SEC ID NO: 2 y una CDR3 que consiste en la secuencia de aminoácidos de los números de aminoácidos 98 a 108 de la SEC ID NO: 2, una región variable de cadena ligera que comprende una CDR1 que consiste en la secuencia de aminoácidos de los números de aminoácidos 24 a 38 de la SEC ID NO: 4, una CDR2 que consiste en la secuencia de aminoácidos de los números de aminoácidos 54 a 60 de la SEC ID NO: 4, una CDR3 que consiste en la secuencia de aminoácidos de los números de aminoácidos 93 a 101 de la SEC ID NO: 4 y una región constante de cadena pesada que es una región constante de Ig?1 humana que tiene las mutaciones de aminoácidos de S239D, H268D y L328W.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014160141 | 2014-08-06 | ||
| PCT/JP2015/072162 WO2016021621A1 (ja) | 2014-08-06 | 2015-08-05 | 新規抗ヒトＩｇβ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001642A true MX2017001642A (es) | 2017-04-27 |
| MX384640B MX384640B (es) | 2025-03-14 |
Family
ID=55263882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001642A MX384640B (es) | 2014-08-06 | 2015-08-05 | ANTICUERPO IGß ANTIHUMANO NOVEDOSO. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10316086B2 (es) |
| EP (1) | EP3178929B1 (es) |
| JP (1) | JP6627761B2 (es) |
| KR (1) | KR102488214B1 (es) |
| CN (1) | CN106574259B (es) |
| AR (1) | AR102042A1 (es) |
| AU (1) | AU2015300080B2 (es) |
| CA (1) | CA2957313C (es) |
| ES (1) | ES2886443T3 (es) |
| IL (1) | IL250404B (es) |
| MA (1) | MA40321A (es) |
| MX (1) | MX384640B (es) |
| MY (1) | MY181914A (es) |
| PH (1) | PH12017500201B1 (es) |
| PL (1) | PL3178929T3 (es) |
| PT (1) | PT3178929T (es) |
| RU (1) | RU2710532C2 (es) |
| SG (1) | SG11201700885SA (es) |
| TW (1) | TWI681971B (es) |
| UA (1) | UA121866C2 (es) |
| WO (1) | WO2016021621A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP7538131B2 (ja) | 2019-01-28 | 2024-08-21 | 上海拓界生物医薬科技有限公司 | 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254302B (zh) * | 1999-05-07 | 2011-05-11 | 杰南技术公司 | 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病 |
| US20020150573A1 (en) * | 2000-11-10 | 2002-10-17 | The Rockefeller University | Anti-Igalpha-Igbeta antibody for lymphoma therapy |
| WO2003027151A1 (en) * | 2001-09-25 | 2003-04-03 | Immuno-Biological Laboratories Co., Ltd. | Recombinant anti-osteopontin antibody and use thereof |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| WO2012018687A1 (en) | 2010-08-02 | 2012-02-09 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5553989B2 (ja) * | 2005-06-01 | 2014-07-23 | カリフォルニア インスティテュート オブ テクノロジー | ウィルスベクターを使用した標的化遺伝子送達方法 |
| AU2006297304B2 (en) * | 2005-09-29 | 2012-05-17 | Medimmune, Llc | Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
| JP5087625B2 (ja) * | 2006-09-01 | 2012-12-05 | セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド | 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化 |
| EP2176298B1 (en) * | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| SI2176296T1 (sl) | 2007-07-16 | 2012-05-31 | Genentech Inc | Protitelesa proti CD b in imunokonjugati in postopki za uporabo |
| ES2643239T3 (es) | 2008-01-31 | 2017-11-21 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
-
2015
- 2015-08-05 KR KR1020177003135A patent/KR102488214B1/ko active Active
- 2015-08-05 MX MX2017001642A patent/MX384640B/es unknown
- 2015-08-05 PT PT158291542T patent/PT3178929T/pt unknown
- 2015-08-05 RU RU2017106743A patent/RU2710532C2/ru active
- 2015-08-05 AR ARP150102510A patent/AR102042A1/es active IP Right Grant
- 2015-08-05 TW TW104125426A patent/TWI681971B/zh active
- 2015-08-05 MY MYPI2017700380A patent/MY181914A/en unknown
- 2015-08-05 WO PCT/JP2015/072162 patent/WO2016021621A1/ja not_active Ceased
- 2015-08-05 SG SG11201700885SA patent/SG11201700885SA/en unknown
- 2015-08-05 EP EP15829154.2A patent/EP3178929B1/en active Active
- 2015-08-05 IL IL250404A patent/IL250404B/en unknown
- 2015-08-05 ES ES15829154T patent/ES2886443T3/es active Active
- 2015-08-05 US US15/501,626 patent/US10316086B2/en active Active
- 2015-08-05 CA CA2957313A patent/CA2957313C/en active Active
- 2015-08-05 CN CN201580042306.6A patent/CN106574259B/zh active Active
- 2015-08-05 UA UAA201702067A patent/UA121866C2/uk unknown
- 2015-08-05 JP JP2016540256A patent/JP6627761B2/ja active Active
- 2015-08-05 MA MA040321A patent/MA40321A/fr unknown
- 2015-08-05 PL PL15829154T patent/PL3178929T3/pl unknown
- 2015-08-05 AU AU2015300080A patent/AU2015300080B2/en active Active
-
2017
- 2017-02-02 PH PH12017500201A patent/PH12017500201B1/en unknown
-
2019
- 2019-04-23 US US16/392,418 patent/US11059889B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001642A (es) | ANTICUERPO IGß ANTIHUMANO NOVEDOSO. | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| CL2018002792A1 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos. | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| PE20190212A1 (es) | Anticuerpos anti_ige | |
| EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
| PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| MX392340B (es) | Anticuerpo anti cd73 humana. | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| MX380937B (es) | Anticuerpos dobles especificos. | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| EA201690803A1 (ru) | Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов | |
| EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ |